Biotech Values

[mcbio]

Re: CYPB/BLRX royalties

Specific terms of the transaction were not disclosed, but the total upfront payment to BioLineRx was $30 million, with total potential clinical and regulatory milestones of up to $160 million through to approval in the United States (the majority of which are related to improvement in cognition), potential commercial milestones of $85 million, and a potential additional $90 million associated with approval for additional indications in the United States or for approval in other countries in North America. In addition, Cypress will fund all continuing development activities and pay BioLineRx a royalty based on applicable sales.

It doesn't say it in this PR, but the Reuters PR (http://www.reuters.com/article/idCALDE65J03G20100620?rpc=44 ) reflects that BLRX will receive royalties of "12 to 18 percent based on sales."

Is this a drug that, if successful, CYPB could bring to market on its own or would they need to further enter into a deal with a big pharma?